KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
KALA BIO (NASDAQ:KALA) has announced a virtual Key Opinion Leader (KOL) event scheduled for July 16, 2025, at 4:00 p.m. ET. The event will focus on KPI-012, their investigational treatment for persistent corneal epithelial defect (PCED).
The webcast will feature presentations from distinguished ophthalmology experts including Dr. Francis Mah from Scripps Clinic, Dr. Anthony Aldave from Jules Stein Eye Institute, Dr. Stephen Pflugfelder from Baylor College of Medicine, and Dr. Melissa Toyos from Toyos Clinic. The discussion will cover PCED disease overview, unmet needs, and insights into the CHASE clinical trial. Todd Bazemore, interim CEO, will discuss KPI-012's commercial potential and upcoming milestones.
KALA BIO (NASDAQ:KALA) ha annunciato un evento virtuale con Key Opinion Leader (KOL) previsto per il 16 luglio 2025, alle 16:00 ET. L'evento sarà incentrato su KPI-012, il loro trattamento sperimentale per il difetto epiteliale corneale persistente (PCED).
La trasmissione in webcast presenterà interventi di rinomati esperti di oftalmologia, tra cui Dr. Francis Mah della Scripps Clinic, Dr. Anthony Aldave del Jules Stein Eye Institute, Dr. Stephen Pflugfelder del Baylor College of Medicine e Dr. Melissa Toyos della Toyos Clinic. La discussione tratterà una panoramica della malattia PCED, le esigenze non soddisfatte e approfondimenti sullo studio clinico CHASE. Todd Bazemore, CEO ad interim, parlerà del potenziale commerciale di KPI-012 e delle prossime tappe importanti.
KALA BIO (NASDAQ:KALA) ha anunciado un evento virtual con Key Opinion Leaders (KOL) programado para el 16 de julio de 2025 a las 4:00 p.m. ET. El evento se centrará en KPI-012, su tratamiento en investigación para el defecto epitelial corneal persistente (PCED).
La transmisión en línea contará con presentaciones de destacados expertos en oftalmología, incluyendo al Dr. Francis Mah de Scripps Clinic, Dr. Anthony Aldave del Jules Stein Eye Institute, Dr. Stephen Pflugfelder del Baylor College of Medicine y Dr. Melissa Toyos de Toyos Clinic. La discusión abordará una visión general de la enfermedad PCED, las necesidades no cubiertas y detalles del ensayo clínico CHASE. Todd Bazemore, CEO interino, hablará sobre el potencial comercial de KPI-012 y los próximos hitos.
KALA BIO (NASDAQ:KALA)는 2025년 7월 16일 오후 4시(동부시간)에 예정된 가상 Key Opinion Leader(KOL) 행사를 발표했습니다. 이번 행사는 지속성 각막 상피 결손증(PCED) 치료제인 KPI-012에 초점을 맞춥니다.
웹캐스트에는 Scripps Clinic의 Dr. Francis Mah, Jules Stein Eye Institute의 Dr. Anthony Aldave, Baylor College of Medicine의 Dr. Stephen Pflugfelder, Toyos Clinic의 Dr. Melissa Toyos 등 저명한 안과 전문가들이 참여합니다. 논의 내용은 PCED 질환 개요, 미충족 의료 수요, CHASE 임상시험에 대한 통찰을 포함합니다. 임시 CEO인 Todd Bazemore는 KPI-012의 상업적 잠재력과 향후 주요 일정에 대해 설명할 예정입니다.
KALA BIO (NASDAQ:KALA) a annoncé un événement virtuel avec des Key Opinion Leaders (KOL) prévu pour le 16 juillet 2025 à 16h00 ET. L'événement portera sur KPI-012, leur traitement expérimental pour le défaut épithélial cornéen persistant (PCED).
Le webinaire comprendra des présentations d'experts en ophtalmologie renommés, notamment Dr. Francis Mah de la Scripps Clinic, Dr. Anthony Aldave de l'Institut Jules Stein, Dr. Stephen Pflugfelder du Baylor College of Medicine, et Dr. Melissa Toyos de la clinique Toyos. La discussion abordera un aperçu de la maladie PCED, les besoins non satisfaits, ainsi que des informations sur l'essai clinique CHASE. Todd Bazemore, PDG par intérim, présentera le potentiel commercial de KPI-012 et les prochaines étapes importantes.
KALA BIO (NASDAQ:KALA) hat eine virtuelle Key Opinion Leader (KOL)-Veranstaltung angekündigt, die für den 16. Juli 2025 um 16:00 Uhr ET geplant ist. Der Fokus der Veranstaltung liegt auf KPI-012, ihrer experimentellen Behandlung für persistierende Hornhautepitheldefekte (PCED).
Die Webcast-Präsentationen werden von renommierten Ophthalmologie-Experten gehalten, darunter Dr. Francis Mah von der Scripps Clinic, Dr. Anthony Aldave vom Jules Stein Eye Institute, Dr. Stephen Pflugfelder vom Baylor College of Medicine und Dr. Melissa Toyos von der Toyos Clinic. Die Diskussion umfasst einen Überblick über die PCED-Erkrankung, bestehende unerfüllte Bedürfnisse und Einblicke in die CHASE-Studie. Todd Bazemore, Interim-CEO, wird das kommerzielle Potenzial von KPI-012 und bevorstehende Meilensteine erläutern.
- None.
- None.
ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss the potential of KPI-012 for the treatment of persistent corneal epithelial defect (PCED). The event will take place on Wednesday, July 16, 2025, at 4:00 p.m. ET.
The webcast event will feature presentations from:
- Francis Mah, M.D., Director of Cornea and External Disease & Co-Director, Refractive Surgery at Scripps Clinic Medical Group
- Anthony Aldave, M.D., Professor of Ophthalmology, Co-Chief of the Cornea and Uveitis Division at Jules Stein Eye Institute
- Stephen Pflugfelder, M.D., Professor and James and Margret Elkins Chair in Ophthalmology at Baylor College of Medicine
- Melissa Toyos, M.D., Partner, Research Director, Comprehensive Ophthalmology at Toyos Clinic
The speakers will provide a disease overview of PCED, including the unmet need and patient journey, as well as insights into mesenchymal stem cell secretome (MSC-S), KPI-012 and the CHASE clinical trial experience. In addition, Todd Bazemore, interim Chief Executive Officer and President of KALA BIO, will review the commercial opportunity of KPI-012 and upcoming milestones.
There will be an opportunity for Q&A following the presentation. Participants can register for the live webcast here. In addition, a live webcast of the presentation will be available under “Presentations” in the Investor section of the Company’s website at www.kalarx.com. An archived replay will be available on the Company's website following the presentation.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When is KALA BIO's KOL event for KPI-012 and how can investors attend?
Who are the key speakers at KALA BIO's KPI-012 KOL event?
What topics will be covered at KALA's KPI-012 KOL event?
Where can investors access the replay of KALA's KPI-012 KOL presentation?
